Anders Jack

CFO Anders Jack sold 10,000 shares of RVMD at $98.00 on 2026-01-07; stock now at $118.64, near 52-week high.

Anders Jack sold 10,000 shares (8.5% of holdings) at $98.00, just 20 days before current price of $118.64—a transaction executed well below the 52-week high and during a powerful 52.3% rally over the past 30 days. At his same ticker, Revolution Medicines, Jack has an established pattern of well-timed exits: his prior two measurable sales (2024-10-11 and 2023-09-01) both preceded 90-day declines of -11.7% and -33.4% respectively, yielding a 2-of-2 well-timed rate at RVMD. However, the company remains deeply unprofitable with $-305.2M annual net income and zero quarterly revenue, creating structural uncertainty. The sale's timing—before a sharp rally—diverges from Jack's historical tendency to sell ahead of downturns, suggesting either a near-term execution need or a shift in the typical pattern at this biotech with volatile price action.

CFO Anders Jack sold 10,000 shares at $64.00 (stock up +35.5% in 30d, +77.3% in 90d); sells all well-timed at 90-day mark historically at RVMD.

Anders Jack, CFO of Revolution Medicines, sold 10,000 shares for $640,000 on 2025-11-11 at $64.00, reducing his holdings from 121.0K to 111.0K shares (8.3% reduction). The timing context is notable: RVMD has surged +35.5% over the prior 30 days and +77.3% over the prior 90 days, putting the stock within striking distance of its 52-week high of $65.83. His cross-ticker track record shows a 100.00% well-timed rate on 2 prior sells (negative 90-day returns), and at RVMD specifically, both prior sales (2024-10-11 and 2023-09-01) were followed by 90-day declines of 11.7% and 33.4% respectively, suggesting a pattern of selling ahead of pullbacks. The company's fundamentals remain challenged: latest quarter revenue was $0.00, the company posted a $-305.2M net loss for the most recent full year, and annual revenue growth was -100.0%, indicating a loss of commercial revenue. The combination of well-documented historical timing skill at this ticker, sharp recent price momentum, and persistent unprofitability creates a material signal for investors monitoring insider positioning.

CFO Anders Jack sold 10,000 RVMD shares at $50.30; prior same-ticker sale (2023-09-01) posted -33.4% return at 90 days.

Anders Jack, CFO of Revolution Medicines, sold 10,000 shares at $50.30 on 2024-10-11, reducing his holdings from 108,932 to 98,932 shares. This transaction occurs in an unprofitable company with negative net income of $-133.2M in the latest quarter and annual revenue decline of -67.3%, against a market cap of $8.2B. Notably, Jack's prior sale at RVMD on 2023-09-01 was well-timed at the 90-day horizon with a return of -33.4%, meaning the stock fell after that sale. His cross-ticker track record shows a 100.00% well-timed rate on prior sells with an average 90-day return of -33.4%, suggesting a pattern of selling before downturns. The current stock price of $48.99 is -3.0% from its 52-week high of $50.48, near the transaction price level, providing a near-term test of whether this sale again precedes a material decline.